The grant is a modest positive for Pulsenmore's AI roadmap but does not change near-term financials. Monitor for clinical validation results and potential partnership expansions with Clalit and other HMOs. No immediate trading catalyst.
Price Chart
Executive Summary
Pulsenmore announced its selection for a $1 million AI development project under the Israel Innovation Authority and Ministry of Health's Healthcare AI Regulatory Sandbox Program. The non-dilutive grant will fund clinical validation of AI applications for its home ultrasound platform, but the immediate financial impact is minimal relative to the $25M market cap.
Key Facts
- Selected for Israel Innovation Authority and Ministry of Health program to lead a $1 million AI development project.
- Project aims to develop and clinically validate AI applications to improve workflow efficiency and scalability of the home ultrasound platform.
- Collaboration with Beilinson Hospital (Clalit Health Services network) for development and clinical validation.
- Over 250,000 home ultrasound scans performed to date, providing a large dataset for AI training.
- Funding is non-dilutive and supports regulatory sandbox framework for AI integration.
Financial Impact
Up to $1 million in non-dilutive funding from the Israel Innovation Authority for AI development; no revenue or earnings impact disclosed.
Risk Factors
- Project outcomes are uncertain and depend on successful clinical validation.
- AI development may not lead to commercial adoption or revenue generation.
- Small grant size relative to cash burn may not materially extend runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-032932 |
| Document: form6-k.htm | 0001493152-26-032932 |
| Document: 0001493152-26-032932-index-headers.html | 0001493152-26-032932 |
| Document: 0001493152-26-032932-index.html | 0001493152-26-032932 |
| Document: 0001493152-26-032932.txt | 0001493152-26-032932 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $1.90 | awaiting T+20 | — | $1.77 (−6.84%) |
Oct 8, 2026 18d ago | SC 13G | $1.85 | awaiting T+20 | — | $1.77 (−4.32%) |
Sep 17, 2026 5w ago | 6-K | $2.42 $1.81 | ▼ −25.21% | ▼ −26.41% | $1.77 (−26.86%) |
Sep 8, 2026 6w ago | 6-K | $2.46 $2.16 | ▼ −12.20% | ▼ −13.91% | $1.77 (−28.05%) |
Sep 2, 2026 7w ago | EFFECT | $2.55 $2.22 | ▲ +12.94% | ▲ +12.86% | $1.77 (+30.59%) |
Aug 31, 2026 8w ago | 6-K | $2.62 $2.19 | ▼ −16.41% | ▼ −16.22% | $1.77 (−32.44%) |
Aug 19, 2026 9w ago | 6-K | $3.01 $2.42 | ▼ −19.60% | ▼ −18.76% | $1.77 (−41.20%) |
Aug 17, 2026 10w ago | 6-K | $2.89 $2.41 | ▼ −16.61% | ▼ −14.63% | $1.77 (−38.75%) |
Jul 13, 2026 15w ago | 6-K | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.77 (−51.10%) |
Jul 13, 2026 15w ago | EFFECT | $3.62 $3.26 | ▼ −9.94% | ▼ −13.13% | $1.77 (−51.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers